Astellas Pharma Inc. - Depreciation and Amortization Expense
Astellas Pharma Inc.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Depreciation-and-Amortization-Expense" stands at 48.64 Billion Japanese Yens for the trailing twelve months (TTM) period ending 12/31/2024, the lowest value since 03/31/2014.'
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -63.21 percent compared to the value the year prior.
The 1 year change in percent is -63.21.
The 3 year change in percent is -36.96.
The 5 year change in percent is -23.99.
The 10 year change in percent is -24.51.
The Serie's change in percent from it's minimum value, on 06/30/2013, to it's latest available value, on 12/31/2024, is +210.30%.
The Serie's change in percent from it's maximum value, on 03/31/2024, to it's latest available value, on 12/31/2024, is -69.18%.
Depreciation and Amortization Expense for Related Companies:
| Logo | Name | Market Cap (USD) |
|---|---|---|
 | Eli Lilly and Company - Depreciation and Amortization Expense | 905,699,262,464.00 |
 | Johnson & Johnson - Depreciation and Amortization Expense | 486,508,953,600.00 |
 | AbbVie Inc - Depreciation and Amortization Expense | 399,570,305,024.00 |
 | Roche Holding AG - Depreciation and Amortization Expense | 317,433,206,677.55 |
 | AstraZeneca PLC - Depreciation and Amortization Expense | 280,205,508,085.11 |